Diabetic Medicine

The future of glucose sensors—using the technology within a clinical service
pp. 195-196(2)
Author: Flanagan, D. E.

Glucose sensors: a review of current and emerging technology
pp. 197-210(14)
Authors: Oliver, N. S.; Toumazou, C.; Cass, A. E. G.; Johnston, D. G.

Insulin sensitivity increase after calcium supplementation and change in intraplatelet calcium and sodium-hydrogen exchange in hypertensive patients with Type 2 diabetes
pp. 211-219(9)
Authors: Pikilidou, M. I.; Lasaridis, A. N.; Sarafidis, P. A.; Befani, C. D.; Koliakos, G. G.; Tziolas, I. M.; Kazakos, K. A.; Yovos, J. G.; Nilsson, P. M.

Inflammation, hepatic enzymes and resistance training in individuals with metabolic risk factors
pp. 220-227(8)
Authors: Levinger, I.; Goodman, C.; Peake, J.; Garnham, A.; Hare, D. L.; Jerums, G.; Selig, S.

Prevalence of GORD (gastro-oesophageal reflux disease) in Type 2 diabetes and a comparison of clinical profiles between diabetic patients with and without GORD
pp. 228-233(6)
Authors: Horikawa, A.; Ishii-Nozawa, R.; Ohguro, M.; Takagi, S.; Ohtuji, M.; Yamada, M.; Kuzuya, N.; Ujihara, N.; Ujihara, M.; Takeuchi, K.

The effect of a cognitive or motor task on gait parameters of diabetic patients, with and without neuropathy
pp. 234-239(6)
Authors: Paul, L.; Ellis, B. M.; Leese, G. P.; McFadyen, A. K.; McMurray, B.

Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy
pp. 240-246(7)
Authors: Bril, V.; Tomioka, S.; Buchanan, R. A.; Perkins, B. A.

Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage
pp. 247-252(6)
Authors: Deguchi, T.; Hashiguchi, T.; Horinouchi, S.; Uto, T.; Oku, H.; Kimura, K.; Makisumi, K.; Arimura, K.

Body mass index and risk of all-cause and cardiovascular mortality in hospitalized elderly patients with diabetes mellitus
pp. 253-259(7)
Authors: Weiss, A.; Boaz, M.; Beloosesky, Y.; Kornowski, R.; Grossman, E.

Safety and efficacy of inhaled insulin (AERx^® iDMS ) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial
pp. 260-267(8)
Authors: Moses, R. G.; Bartley, P.; Lunt, H.; O'Brien, R. C.; Donnelly, T.; Gall, M.-A.; Vesterager, A.; Wollmer, P.; Roberts, A.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
pp. 268-278(11)
Authors: Marre, M.; Shaw, J.; Brändle, M.; Bebakar, W. M. W.; Kamaruddin, N. A.; Strand, J.; Zdravkovic, M.; Le Thi, T. D.; Colagiuri, S.

Children and adolescents on intensive insulin therapy maintain postprandial glycaemic control without precise carbohydrate counting
pp. 279-285(7)
Authors: Smart, C. E.; Ross, K.; Edge, J. A.; Collins, C. E.; Colyvas, K.; King, B. R.

Implementation of a systematic approach to diabetes in primary care in Bahia, Brazil improves metabolic outcomes: PRODIBA—Programa de Interiorização da Assistência ao Diabetes na Bahia (Project for Dissemination of Diabetes Care in the State of Bahia)
pp. 286-292(7)
Authors: Chaves-Fonseca, R. M.; Matos, O. S.; Lordelo, Roberta A.; Abreu, M.; Farias, M. G.; Coutinho, J. F.; Ribeiro, M. N.; Matteoni-Athayde, L.; Lessa, I.; Pousada, J.; Oliveira, M.; Lopes, C.; Strock, E.; Mazze, R.

A randomized trial investigating the 12-month changes in physical activity and health outcomes following a physical activity consultation delivered by a person or in written form in Type 2 diabetes: Time2Act
pp. 293-301(9)
Authors: Kirk, A.; Barnett, J.; Leese, G.; Mutrie, N.

Sudomotor dysfunction is associated with foot ulceration in diabetes
pp. 302-305(4)
Authors: Tentolouris, N.; Marinou, K.; Kokotis, P.; Karanti, A.; Diakoumopoulou, E.; Katsilambros, N.

The metabolic syndrome: in need of a global mission statement
pp. 306-309(4)
Authors: Cameron, A. J.; Zimmet, P. Z.; Shaw, J. E.; Alberti, K. G. M. M.

National Institute for Clinical Excellence (NICE) and the post-partum fasting glucose: are patients with Type 2 diabetes mellitus being missed?
pp. 310-311(2)
Authors: Ng, J. M.; Medlock, R.; Wilkinson, L.; Lindow, S. W.; Masson, E. A.; Allan, B.

Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion
pp. 311-312(2)
Authors: Siebenhofer, A.; Jeitler, K.; Berghold, A.; Horvath, K.; Pieber, T. R.

Author's response
pp. 312-313(2)
Author: Pickup, J. C.

Authors' response to `Comments on the use of bemiparin in diabetic foot ulcers'
pp. 313-314(2)
Authors: Rullan, M.; Cerdà, L.; Frontera, G.; Masmiquel, L.; Llobera, J.